J Intern Med:瑞舒伐他汀治疗慢性阻塞性肺疾病COPD的研究

2015-06-01 徐媛媛译 MedSci原创

本研究的旨在研究是否可以通过他汀类药物增强内皮依赖性的血管功能来改善COPD患者的肺功能,减少系统性炎症。 研究人员在挪威两所大学对COPD患者进行了一项随机、安慰剂对照、双盲、平行试验。将在稳定期的慢性阻塞性肺病COPD患者(n = 99)随机分配:接受每日一次共12周的10mg瑞舒伐他汀组(n=49)或与之相匹配的安慰剂组(n=50)。主要结局是使用外周动脉张力测定法和表达为反应性充血指数来

本研究的旨在研究是否可以通过他汀类药物增强内皮依赖性的血管功能来改善COPD患者的肺功能,减少系统性炎症。

研究人员在挪威两所大学对COPD患者进行了一项随机、安慰剂对照、双盲、平行试验。将在稳定期的慢性阻塞性肺病COPD患者(n = 99)随机分配:接受每日一次共12周的10mg瑞舒伐他汀组(n=49)或与之相匹配的安慰剂组(n=50)。主要结局是使用外周动脉张力测定法和表达为反应性充血指数来测定内皮依赖性血管功能。次要结局评估1s(FEV1)、FEV1/FVC以及炎症标记物白介素-6(IL6)和高灵敏度循环水平C-反应蛋白(hsCRP)的变化来确定。

在所有研究组群中,在血管内皮依赖性血管功能或肺功能的改变上并无显著组间差异。与安慰剂相比,瑞舒伐他汀治疗组hsCRP水平降低(-20% vs 11%,P =0.017)以及IL6浓度上升趋势减缓(8% vs 30%,p =0.028)。在预设的亚组分析中,超过中位数循环hsCRP浓度(>1.7mg/L)患者中,瑞舒伐他汀与内皮依赖性血管功能(13% vs 2%,P =0.026)相关。

在没有他汀类药物治疗的标准的稳定期的慢性阻塞性肺病患者中,瑞舒伐他汀用于治疗全身性炎症症状的患者,与其全身性炎症的消退和内皮依赖性血管功能的改善可能相关。

原始出处

Neukamm A1, Høiseth AD, Einvik G, Lehmann S, Hagve T, Søyseth V, Omland T.Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.J Intern Med. 2014 Dec 11

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696649, encodeId=057e1696649bc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Sep 24 00:25:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38426, encodeId=082d384262b, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:42:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606515, encodeId=f58d1606515d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 03 07:25:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25735, encodeId=fbbe25e354d, content=他汀抗炎,作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 01 21:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=)]
    2015-09-24 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696649, encodeId=057e1696649bc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Sep 24 00:25:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38426, encodeId=082d384262b, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:42:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606515, encodeId=f58d1606515d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 03 07:25:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25735, encodeId=fbbe25e354d, content=他汀抗炎,作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 01 21:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=)]
    2015-10-11 hlycom3356

    感谢作者分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1696649, encodeId=057e1696649bc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Sep 24 00:25:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38426, encodeId=082d384262b, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:42:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606515, encodeId=f58d1606515d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 03 07:25:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25735, encodeId=fbbe25e354d, content=他汀抗炎,作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 01 21:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696649, encodeId=057e1696649bc, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Sep 24 00:25:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38426, encodeId=082d384262b, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:42:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606515, encodeId=f58d1606515d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 03 07:25:00 CST 2015, time=2015-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25735, encodeId=fbbe25e354d, content=他汀抗炎,作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Mon Jun 01 21:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=)]
    2015-06-01 medcardio

    他汀抗炎,作用

    0

相关资讯

ESC 2013:韩雅玲教授发现瑞舒伐他汀可显著降低DM合并慢性肾病患者的对比剂急性肾损伤风险

研究要点: 造影剂急性肾损伤(CIAKI)是使用造影剂的重要并发症,此前已有小型研究结果显示,他汀类药物治疗可减少CIAKI发病风险,但他汀治疗对CIAKI的预防作用尚不明确。 这项研究表明,罗素伐他汀可显著降低糖尿病合并慢性肾脏病患者CIAKI发生率。 韩雅玲

ACC 2014:瑞舒伐他汀治疗儿童和青少年HeFH患者动脉壁的变化(CHARON研究)

    平均颈动脉内膜中层厚度(cIMT)是成人未来冠心病发生率的预测因素。已证实,瑞舒伐他汀在年龄为10~18岁的儿童和青少年中显著降低低密度脂蛋白胆固醇(LDL-C)水平。     CHARON研究纳入198例年龄为6~17岁的杂合子家族性高胆固醇血症(HeFH)儿童患者,患者空腹LDL-C>190mg/dl(>4.9 mmol/L)

ACC 2014:瑞舒伐他汀治疗可减小富含脂质斑块体积(CHALLENGER研究)

研究背景       颈动脉粥样硬化常通过测定动脉内膜中层厚度(IMT)来诊断,但颈动脉粥样硬化斑块体积及其组成可较IMT更好地预测患者的冠状动脉事件。高分辨率磁共振成像(MRI)是一种非侵入性创新技术,其可从定量水平、形态学和组成方面评估颈动脉斑块。因此,CHALLENGER研究应用MRI评估了日本人群进行瑞舒伐他汀治疗对其颈动脉粥样

ESC 2014:高强度瑞舒伐他汀可改善非梗死相关动脉粥样硬化(IBIS 4试验)

ESC2014公布的一项研究表明,在ST段抬高性心肌梗死(STEMI)患者中,高强度瑞舒伐他汀治疗与非梗死相关动脉粥样硬化减退具有相关性,坏死核和斑块表型无变化。论文于9月4日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入103例在成功经皮冠状动脉介入治疗(PCI)后接受血管内超声(IVUS)和射频超声(RF-IVUS)检查的STEMI患者;两处非梗死相关性心外膜冠状

瑞舒伐他汀可减轻系统性硬化症内皮功能障碍

柏林(EGMN)——在欧洲风湿病学大会(ECR)年会上,匈牙利德布勒森大学的Gabriella Szucs博士报告了首个瑞舒伐他汀治疗系统性硬化症(SS)的研究结果:6个月的瑞舒伐他汀(可定)治疗可显著减轻SS患者内皮功能障碍并降低C-反应蛋白(CRP)水平。 目前对病情持续进展的SS患者病尚无基础用药或缓解病情的治疗药物。内皮功能障碍是SS发病机制的第一步,如果能够改善内皮功能则有可能减缓疾病进

SATURN 研究解读:阿托伐他汀征战动脉粥样硬化

专家解读SATURN 研究 征战动脉粥样硬化,阿托伐他汀再添新证   2011 年11 月15 日,美国AHA 年会上,SATURN(采用血管内超声研究冠脉粥样硬化:瑞舒伐他汀和阿托伐他汀的疗效比较)研究结果在最新揭晓的临床研究专场公布,并同期在《新英格兰医学杂志》在线发表。这项头对头、比较大剂量他汀对动脉粥样硬化斑块影响的临床试验为强化他汀治疗、逆转斑块的作用增添了新的有利证据,